Bracco Diagnostics Inc. Makes New Syringe Packs Available for Use with EmpowerCTA® Computed Tomography Contrast Delivery

  Bracco Diagnostics Inc. Makes New Syringe Packs Available for Use with
  EmpowerCTA® Computed Tomography Contrast Delivery Systems

Business Wire

MONROE TOWNSHIP, N.J. -- October 11, 2013

Bracco Diagnostics Inc., the U.S. subsidiary of Bracco Imaging S.p.A, recently
announced the availability of syringe packs with spikes, to be used when
loading contrast and saline for delivery with power injectors in computed
tomography (CT) suites.

Bracco syringe packs are specifically designed for use with the EmpowerCTA and
Empower CT contrast delivery systems, offering greater flexibility in contrast
and saline preparation. According to Terry Heagy, Senior Device Business
Manager, Bracco Diagnostics Inc., “These new syringe packs reduce
opportunities for contamination, help reduce contrast mess and allow efficient
contrast loading.” Heagy also noted that the new spikes work with all volumes
of contrast and saline to promote workflow efficiencies and ease of use. In
addition, Bracco syringe packs with spikes conform to the Joint Commission’s
“Elements of Performance for Medication Management,” as it pertains to
standards for hospitals safely preparing medications.*

About EmpowerCTA

The EmpowerCTA Contrast Injection System is a dual head injector, designed to
optimize the delivery of iodinated X-ray contrast media and saline flush in
the dual head configuration during computed tomography (CT) procedures. The
EmpowerCTA Contrast Injection System is rated among the safest injectors in
the industry and is used in major teaching institutions in the United States.
The EmpowerCTA has a built-in estimated Glomerular Filtration Rate (eGFR)
calculator and a fully integrated Extravasation Detection Accessory (EDA™).

DISCLAIMER

Not all products are available in all global markets. Please refer to your
local distributor or agent.

EmpowerCTA is designed for the vascular administration of contrast and
flushing media in conjunction with computed tomography (CT) scanning of the
body. The EDA is intended to detect extravasations of contrast media during
powered CT contrast injections.

EmpowerCTA and EmpowerCT are registered trademarks of Bracco Injeneering SA,
registered in the United States.

EDA is a registered trademark of Bracco Injeneering SA, registered in the
United States.

Bracco Diagnostics Inc., reserves the right to modify the specifications and
features described herein, or discontinue manufacture of the product described
at any time without prior notice or obligation.

Please contact your authorized Bracco Injeneering SA representative for the
most updated information.

For additional information about Bracco’s products, and for full prescribing
information, please visit http://imaging.bracco.com/us-en. If you have any
questions or require additional information about any Bracco product, please
contact Bracco Professional Services at 1-800-257-5181, option 2.

About Bracco Imaging

Bracco Imaging S.p.A., part of the Bracco Group, is one of the world’s leading
companies in the diagnostic imaging business. Headquartered in Milan, Italy,
Bracco Imaging develops, manufactures and markets diagnostic imaging agents
and solutions that meet medical needs.

Bracco Imaging offers a product and solution portfolio for all key diagnostic
imaging modalities: X-Ray Imaging (including Computed Tomography-CT,
Interventional Radiology, and Cardiac Catheterization), Magnetic Resonance
Imaging (MRI), Contrast Enhanced Ultrasound (CEUS), Nuclear Medicine through
radioactive tracers, and Gastrointestinal Endoscopy. The diagnostic imaging
offer is completed by several medical devices and advanced administration
systems for contrast imaging products in the fields of radiology.

The Company operates in over 90 markets worldwide, either directly or
indirectly, through subsidiaries, joint ventures, licenses and distribution
partnership agreements. With an on-going research covering all key modalities,
Bracco Imaging has a strong presence in key geographies: North America; Europe
and Japan operating through the Joint Venture Bracco-Eisai Co., Ltd. The
Company also operates in Brazil, South Korea, and China through the Joint
Venture Bracco Sine Pharmaceutical Corp. Ltd.

Operational investments have been made in order to achieve top quality and
compliance with a sustainable eco-friendly production. Manufacturing
activities are located in Italy, Switzerland, Japan, China and Germany.

Bracco Imaging is an innovative Research and Development (R&D) player with an
efficient process oriented approach and a track record of innovation in the
diagnostic imaging industry. R&D activities are managed in the three Research
Centres located in Italy, Switzerland and the USA.

For additional information – Please Contact Kai Huang, Product Manager.
Kai.Huang@diag.bracco.com - +1 (609) 514-2396.

*Joint Commission 2013, Standard MM.05.01.07 – The hospital safely prepares
medications.

Contact:

Press:
Bracco Diagnostics Inc.
Lakshmi Sundar, 609-514-2236
lakshmi.sundar@diag.bracco.com
 
Press spacebar to pause and continue. Press esc to stop.